Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...